BCG + hsp, a New Tuberculosis Vaccine

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$299,045.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI051832-01A1
Award Id:
66022
Agency Tracking Number:
AI051832
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
SEQUELLA, INC., 9610 MEDICAL CENTER DR, STE 200, ROCKVILLE, MD, 20850
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
BORISNIKONENKO
(301) 762-7776
BORISNIKONENKO@SEQUELLA.COM
Business Contact:
(301) 762-7776
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): This proposal describes research that will examine the safety and efficacy of a novel strain of BCG in which the heat shock repressor gene has been deleted, resulting in the overexpression of a heat shock protein (hsp70). Heat shock proteins show a good deal of promise in the protection against and treatment of tuberculosis, and this novel BCG strain produces a T-cell response indicative of a more protective immune response. The Specific Aims of this Phase I proposal are: 1. In a guinea pig model of tuberculosis (TB), we will compare the efficacies of (1) intradermally administered (i.d.) BCGdeltahspR; (2) i.d. parent BCG; (3) subcutaneously administered (s.c.) BCGdeltahspR; (4) s.c. parent BCG; and (5) no vaccination (control). 2. In a mouse model of tuberculosis, we will compare the efficacies of (1) BCGdeltahspR administered subcutaneously; (2) parent BCG, administered subcutaneously; and (3) no vaccination (control). We believe it is important to test this vaccine in several different strains of mice that represent a spectrum of susceptibility to TB, as it is not known which strain might be the best model of TB in humans. Therefore, we will test the efficacy of rBCGdeltahspR in C57BI6, DBA/2, and CBA. 3. We will examine the safety of this modified BCG as compared to the parent BCG. We will infect mice and guinea pigs with each BCG strain and examine lungs for pathology, and count the CFU of BCG still pre-sent. We will also examine the antibiotic sensitivity of this rBCGdeltahspR to 10 commonly used TB drugs to ensure that the genetic manipulations performed have not made it less sensitive to drug treatment.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government